Kazuhiro Murai
Overview
Explore the profile of Kazuhiro Murai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kudo S, Hikita H, Saito Y, Murai K, Kodama T, Tatsumi T, et al.
Cell Death Differ
. 2025 Feb;
PMID: 39994353
The fine-tuned balance between anti-apoptotic Bcl-2 family proteins, such as Bcl-xL and Mcl-1, and pro-apoptotic Bcl-2 family proteins, like Bak and Bax, is crucial for maintaining hepatocyte integrity. BH3-only proteins,...
2.
Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Ido A, et al.
Hepatol Res
. 2024 Oct;
PMID: 39470448
Aim: The incidence of and factors involved in gastroesophageal varix-related events in hepatitis C virus-related cirrhosis patients, including decompensated cirrhosis, after direct-acting antiviral therapy are unclear. Methods: We conducted a...
3.
Shigeno S, Kodama T, Murai K, Motooka D, Fukushima A, Nishio A, et al.
Cell Mol Gastroenterol Hepatol
. 2024 Sep;
19(1):101412.
PMID: 39349249
Background & Aims: Targeting exhausted immune systems would be a promising therapeutic strategy to achieve a functional cure for HBV infection in patients with chronic hepatitis B (CHB). However, animal...
4.
Sometani E, Hikita H, Murai K, Toyoda H, Tanaka S, Oze T, et al.
Hepatol Res
. 2024 Sep;
PMID: 39291388
Aim: Patients with chronic hepatitis B (CHB) remain at risk for hepatocellular carcinoma (HCC) even with nucleos(t)ide analog therapy. We evaluated risk factors for HCC development, including serum hepatitis B...
5.
Ueyama-Toba Y, Tong Y, Yokota J, Murai K, Hikita H, Eguchi H, et al.
iScience
. 2024 Sep;
27(9):110778.
PMID: 39280628
Human liver organoids derived from primary human hepatocytes (PHHs) are expected to be a hepatocyte source for preclinical studies of drug metabolism and disposition. Because hepatic functions of these organoids...
6.
Sakane S, Hikita H, Shirai K, Sakamoto T, Narumi R, Adachi J, et al.
Hepatol Commun
. 2024 Jun;
8(6).
PMID: 38829196
Background: There is a need for novel noninvasive markers for metabolic dysfunction-associated steatotic liver disease (MASLD) to stratify patients at high risk for liver-related events including liver cancer and decompensation....
7.
Kumazaki S, Hikita H, Tahata Y, Sung J, Fukumoto K, Myojin Y, et al.
Aliment Pharmacol Ther
. 2024 Jun;
60(3):327-339.
PMID: 38828944
Background And Aims: Although metabolic dysfunction-associated steatotic liver disease (MASLD) patients with a Fib-4 index >1.3 are recommended for fibrosis evaluation via elastography or biopsy, a more convenient method identifying...
8.
Sato K, Hikita H, Shigekawa M, Soma K, Yamauchi R, Sung J, et al.
Sci Rep
. 2024 May;
14(1):12028.
PMID: 38797735
Obesity is a risk factor for pancreatic cancer development, partly due to the tissue environment of metabolic disorder-related inflammation. We aimed to detect a tissue environment marker triggered by obesity-related...
9.
Fukuoka M, Kodama T, Murai K, Hikita H, Sometani E, Sung J, et al.
Cancer Sci
. 2024 Jan;
115(3):859-870.
PMID: 38287498
There are approximately 250 million people chronically infected with hepatitis B virus (HBV) worldwide. Although HBV is often integrated into the host genome and promotes hepatocarcinogenesis, vulnerability of HBV integration...
10.
Murai K, Hikita H, Kodama T, Kaibori M, Nishimura Y, Tatsumi T, et al.
Hepatol Res
. 2023 Nov;
54(5):439-450.
PMID: 37983632
Aim: Coronavirus disease 2019 emerged in December 2019 and spread worldwide. This study aimed to clarify the impact of the coronavirus disease 2019 pandemic on the diagnosis and treatment of...